AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18473339
Drug: Pharmacotherapy (fluoxetine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy (fluoxetine)
Trial: 16026803
Drug: IFN beta-1a,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN beta-1a, 22 or 44 mcg subcutaneously three times weekly during years 3 and 4
Trial: 7609864
Drug: B-vitamins (thiamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B-vitamins (thiamine diphosphate 100 mg, pyridoxsine-HCl 200 mg, cyanocobalamin 20 micrograms, p.o.)
Trial: 7609864
Drug: Diclofenac (diclofenac-Na,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (diclofenac-Na, 50 mg, p.o.)
Trial: 2147029
Drug: Isradipine, 14.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine, 14.5 mg once daily
Trial: 381093
Drug: Antacid (Mylanta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid (Mylanta II, 30 ml four times daily and PRN)
Trial: 30285054
Drug: Low-dose amitriptyline
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose amitriptyline (25 mg/d)
Trial: 30285054
Drug: Active comparator
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active comparator (benztropine mesylate, 1 mg/d)
Trial: 25068637
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept 2 mg every 4 weeks for 20 weeks, then as needed (PRN) thereafter.
Trial: 25068637
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment every 4 weeks for 20 weeks, then sham thereafter.
Trial: 22343361
Drug: 3-5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-5 days of antibiotic treatment (group 1)
Trial: 22343361
Drug: 7-10 days
RxNorm normalized name: buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 7-10 days of antibiotic treatment (group 2)
Trial: 12195449
Drug: Comprehensive outpatient
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive outpatient rehabilitative treatment for 6 weeks, 6 days a week.
Trial: 9783376
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg GTN
Trial: 9783376
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg GTN
Trial: 30005989
Drug: Silver sulphadiazine
RxNorm normalized name: Silver sulphadiazine
DrugBank: Silver sulfadiazine (DB05245)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver sulphadiazine cream 10mg/g
Trial: 27001317
Drug: Emollient balm
RxNorm normalized name: Atomic Balm
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emollient balm applied twice a day for 28 days
Trial: 26313719
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg intravenous hydrocortisone administered during anesthetic induction
Trial: 26313719
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no hydrocortisone administered)
Trial: 17131714
Drug: Dose response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose response control dentifrice (250 ppm F; DD)
Trial: 9104712
Drug: Inlay with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inlay with Panavia Ex resin (isthmus width equal to group 3 with lingual and proximal preparation)
Trial: 8064017
Drug: Control periods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control periods (before and after drug administration)
Trial: 3055922
Drug: Lovastatin 20
RxNorm normalized name: lovastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 20 mg nightly (Stratum 1)
Trial: 3055922
Drug: Gemfibrozil 600
RxNorm normalized name: gemfibrozil 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil 600 mg twice daily (Stratum 1)
Trial: 3055922
Drug: Lovastatin 40
RxNorm normalized name: lovastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 40 mg nightly (Stratum 2)
Trial: 3055922
Drug: Gemfibrozil 600
RxNorm normalized name: gemfibrozil 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil 600 mg twice daily (Stratum 2)
Trial: 31770446
Drug: Periarticular injection
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periarticular injection (PAI) with extended-release bupivacaine 266 mg and 20 mL of 0.5% bupivacaine hydrochloride
Trial: 31770446
Drug: Adductor canal
RxNorm normalized name: Canalevia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adductor canal block (ACB) with extended-release bupivacaine 266 mg
Trial: 31719005
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin C (5 g intravenous before anesthesia induction and 5 g in cardioplegic solution)
Trial: 28749549
Drug: Rituximab (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (2 biweekly infusions of 1g each)
Trial: 11820954
Drug: 2HRZS/4HR plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2HRZS/4HR plus vaccine of Mycobacterium vaccae
Trial: 11820954
Drug: 4-6 sensitive
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-6 sensitive antituberculous drugs and vaccine of Mycobacterium vaccae
Trial: 1249190
Drug: Isocaloric diets
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric diets with at least 50 g of carbohydrate
Trial: 28638273
Drug: Nefopam infusion
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam infusion (0.3 mg/kg bolus followed by 65 µg/kg/h infusion)
Trial: 28638273
Drug: Ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusion (0.3 mg/kg bolus followed by 180 µg/kg/h infusion)
Trial: 28638273
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (control group, equal to ketamine infusion)
Trial: 26042362
Drug: CYT003 (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYT003 (0.3 mg)
Trial: 26042362
Drug: CYT003 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYT003 (1 mg)
Trial: 26042362
Drug: CYT003 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYT003 (2 mg)
Trial: 11072779
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (5 g creatine monohydrate, four times daily for 7 days)
Trial: 11072779
Drug: Placebo (glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (glucose capsules, same number as CS)
Trial: 8468527
Drug: High cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High cholesterol diet (HC): 320 mg cholesterol/1000 kcal
Trial: 27110529
Drug: Ketamine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.25 mg/kg) with paracetamol (15 mg/kg)
Trial: 27110529
Drug: Paracetamol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (15 mg/kg) alone
Trial: 17709109
Drug: rosuvastatin 40
RxNorm normalized name: rosuvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 40 mg/day for 4 weeks
Trial: 12370562
Drug: Fish Oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish Oil (FO) 1.8 g of omega‐3 fatty acids x d(‐1)
Trial: 12370562
Drug: Isoflavones (ISO)
RxNorm normalized name: iso-sulfan blue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavones (ISO) 120 mg soy isolate x d(‐1)
Trial: 10583448
Drug: Prazosin pretreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin pretreatment (3 mg) plus smoking
Trial: 10583448
Drug: Atenolol pretreatment
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol pretreatment (50 mg) plus smoking
Trial: 8915027
Drug: Full-mouth disinfection
RxNorm normalized name: moth bean extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-mouth disinfection (scaling and rootplaning in 2 visits within 24 h, tongue brushing with 1% chlorhexidine gel for 1 min, mouth rinsing with 0.2% chlorhexidine solution for 2 min, subgingival irrigation with 1% chlorhexidine gel)
Trial: 26595100
Drug: Fasting blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting blood glucose and randomized insulin treatment strategy
Trial: 25079933
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg prednisolone daily for 2 years (P-group; n=108)
Trial: 19996018
Drug: TEVAR (Thoracic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEVAR (Thoracic Endovascular Aortic Repair) in addition to optimal medical therapy (n=72)
Trial: 19996018
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy alone (n=68)
Trial: 17664199
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (15 mg x kg(‐1) before infusion of heparin and 15 mg x kg(‐1) after protamine infusion)
Trial: 15548814
Drug: Niacin 250
RxNorm normalized name: niacin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin 250 mg
Trial: 15548814
Drug: Niacin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin (both doses)
Trial: 11314677
Drug: 100% daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% daily dose of methadone
Trial: 11314677
Drug: 50% daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% daily dose of methadone
Trial: 11314677
Drug: Methadone (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (both doses)
Trial: 25517733
Drug: 360 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 µg TNF-K (3 injections)
Trial: 25517733
Drug: TNF-K (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF-K (all doses)
Trial: 25517733
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with anti-TNF antibody response
Trial: 25517733
Drug: Patients without
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients without anti-TNF antibody response
Trial: 20362199
Drug: Pre-absorption using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-absorption using serotype 9V
Trial: 20362199
Drug: Pneumococcal conjugate
RxNorm normalized name: pneumococcal conjugate PCV 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal conjugate vaccine (PCV) doses
Trial: 17845107
Drug: Telephone-administered cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-administered cognitive-behavioral therapy (T-CBT) for 16 weeks
Trial: 17845107
Drug: Telephone-administered supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-administered supportive emotion-focused therapy (T-SEFT) for 16 weeks
Trial: 10400054
Drug: Idoxifene 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idoxifene 2.5 mg/day
Trial: 10400054
Drug: Idoxifene 5
RxNorm normalized name: Idoxene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idoxifene 5 mg/day
Trial: 10400054
Drug: Idoxifene 10
RxNorm normalized name: Idoxene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idoxifene 10 mg/day
Trial: 10400054
Drug: Idoxifene (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idoxifene (all doses)
Trial: 7575066
Drug: Epoetin alfa,
RxNorm normalized name: EPOETIN ALFA,RECOMBINANT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin alfa, 150 U/kg, administered subcutaneously three times per week for 6 weeks
Trial: 7575066
Drug: Epoetin alfa,
RxNorm normalized name: EPOETIN ALFA,RECOMBINANT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin alfa, 150 U/kg, administered to patients who were originally receiving placebo for 6 weeks
Trial: 7575066
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered subcutaneously three times per week for 6 weeks
Trial: 27862264
Drug: Every three-hour
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every three-hour oral feeding schedule
Trial: 27862264
Drug: Every six-hour
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every six-hour oral feeding schedule
Trial: 23286782
Drug: Protein and
RxNorm normalized name: Protein and/or protein derivative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein and Ca drink (500 ml)
Trial: 10342804
Drug: Video-enhanced, computer-assisted,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video-enhanced, computer-assisted, self-administered interviews (V-CASI)
Trial: 2387608
Drug: Preanaesthetic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preanaesthetic medication with atropine and retrobulbar injection of xylocaine
Trial: 2387608
Drug: Preanaesthetic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preanaesthetic medication with atropine
Trial: 2387608
Drug: Retrobulbar injection
RxNorm normalized name: LIDOCAINE HYDROCHLORIDE 40 mg in 1 mL RETROBULBAR INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrobulbar injection of xylocaine
Trial: 2387608
Drug: No preanaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preanaesthetic medication with atropine or retrobulbar block with xylocaine
Trial: 30817193
Drug: Biopsy, surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biopsy, surgical or medical therapy, and longitudinal surveillance
Trial: 21830265
Drug: Tailored patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored patient preference intervention including educational and motivational components, simplified dosing regimes, and practical reminders (pill dispensers)
Trial: 11755939
Drug: Experimental yoghurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental yoghurt (3 cups daily providing 1 g of plant stanols)
Trial: 11755939
Drug: Placebo yoghurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo yoghurt (3 cups daily)
Trial: 10523963
Drug: Deoxinate therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deoxinate therapy
Trial: 7263143
Drug: CogentinTM (benztropine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CogentinTM (benztropine mesylate) at increasing doses (maximum 2 mg)
Trial: 30989965
Drug: Bushen Huoxue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bushen Huoxue Anshen Fang (Traditional Chinese Medicine)
Trial: 28980140
Drug: Dexamethasone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (10 mg) and paracetamol (1000 mg)
Trial: 28980140
Drug: Dexamethasone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (10 mg) alone
Trial: 15222836
Drug: Preparing for
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparing for the Drug Free Years program
Trial: 2750998
Drug: Acetazolamide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (1 g, intravenous)
Trial: 24172719
Drug: Cola matched
RxNorm normalized name: cola extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cola matched for caffeine and CHO (CC)
Trial: 19446864
Drug: Aspirin 81
RxNorm normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 81 mg with 400 mg phytosterols
Trial: 19446864
Drug: Non-enteric coated
RxNorm normalized name: diclofenac sodium (enteric coated core) 50 MG / miSOPROStol (non-enteric coated mantle) 200 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-enteric coated aspirin 81 mg
Trial: 1938514
Drug: Low-dose total
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose total body irradiation (TBI)
Trial: 1938514
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (CHVmP)
Trial: 6110090
Drug: 2400 rad
RxNorm normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2400 rad craniospinal radiation therapy (RT)
Trial: 6110090
Drug: 1800 rad
RxNorm normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1800 rad craniospinal radiation therapy (RT)
Trial: 26930603
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (0.3 g/kg)
Trial: 23161047
Drug: Topical latanoprost
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical latanoprost 0.005% (LP)
Trial: 18842999
Drug: Red clover-derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red clover-derived isoflavones (84 mg/d)
Trial: 11134564
Drug: Lower-dose platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose platelet transfusions (38% reduction in mean platelet dose)
Trial: 1488937
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose of alcohol (.75 ml/kg)
Trial: 1488937
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of alcohol (.33 ml/kg)
Trial: 3099267
Drug: Intraglobulin (Biotest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraglobulin (Biotest Pharma, West Germany), 120 mg/kg intravenously, within 2 to 4 hours of delivery (Group A)
Trial: 3099267
Drug: Intraglobulin (Biotest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraglobulin (Biotest Pharma, West Germany), 120 mg/kg intravenously, on days 1 and 8 (Group B)
Trial: 27150393
Drug: 20% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% glucose intravenous infusion
Trial: 27150393
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline intravenous infusion (control)
Trial: 25663170
Drug: L-Dopa carbidopa
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Dopa carbidopa 100 mg
Trial: 25663170
Drug: Pramipexole 1.5
RxNorm normalized name: pramipexole 1.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole 1.5 mg (150 mg LED)
Trial: 17960793
Drug: High-dose calcitriol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose calcitriol (DN-101; 45 mug) plus docetaxel (36 mg/m2)
Trial: 17960793
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus docetaxel (36 mg/m2)
Trial: 16504428
Drug: Oral continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral continuous combined hormone therapy (conjugated equine oestrogens 0.625 mg/d plus medroxyprogesterone acetate 2.5 mg/d or 5 mg/d)
Trial: 14583107
Drug: Standard advanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard advanced cardiac life support (ACLS) intervention and empiric early administration of bicarbonate
Trial: 10892762
Drug: GAD antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD antibodies in SMS patients
Trial: 10892762
Drug: GAD antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD antibodies in T1DM patients
Trial: 1396839
Drug: Nitroglycerin patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin patches (mean necessary effective patch dose: 125 cm2)
Trial: 1396839
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) capsules (administered q5h)
Trial: 1396839
Drug: Placebo patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patches and capsules
Trial: 30561539
Drug: GMZ2 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GMZ2 vaccine (30 or 100 µg formulated in CAF01 or 100 µg formulated in Alhydrogel)
Trial: 30561539
Drug: GMZ2-Alhydrogel (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GMZ2-Alhydrogel (100 µg)
Trial: 30561539
Drug: Baseline vaccine-specific
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline vaccine-specific antibody concentrations
Trial: 25763862
Drug: Golimumab 50
RxNorm normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golimumab 50 mg and 100 mg
Trial: 20858034
Drug: Lidocaine gel
RxNorm normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine gel combined with ketamine (100 mg)
Trial: 20858034
Drug: Lidocaine gel
RxNorm normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine gel combined with normal saline
Trial: 15053030
Drug: Individual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual therapy on request (comparison condition)